Antibody discovery and IP risk: Why freedom to operate matters earlier than you think
In antibody discovery, identifying a promising binder is only part of the challenge. For well-established targets, companies also need to consider whether the resulting sequences are novel, patentable and commercially usable.
Unlocking hard-to-drug targets with VHH antibody discovery
Many high-value therapeutic targets remain difficult to drug, particularly where targets are intracellular, conformationally complex, poorly accessible, highly conserved or embedded in membrane environments.
NGS in antibody discovery: Why sequence depth matters
Next-generation sequencing is changing how antibody discovery teams understand library performance, selection outputs and candidate diversity.
Why Cambridge UK remains a global hub for antibody discovery
Cambridge UK has long been one of the world’s most important centres for life sciences, translational research and biotechnology innovation.
Top 3 tips to ensure you don’t miss out on top talent
By Hayley Murfitt, Director, EA First
Why copying the best might be your worst strategy
By Jonathan Pearce, Co-Founder & Principal Consultant at Alignment Cubed.